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Abstract
A disintegrin and metalloproteinase 17 (ADAM17) is a metalloprotease that is overexpressed in many cancer types,
including renal cancers. However, the regulatorymechanisms of ADAM17 in cancer development and progression are
poorly understood. In the present work, we provide evidence using overexpression and inhibition of microRNA 145
(miR-145) that miR-145 negatively regulates ADAM17 expression. Furthermore, we show that ADAM17 negatively
regulates miR-145 through tumor necrosis factor–α, resulting in a reciprocal negative feedback loop. In this study,
the expression of ADAM17 and miR-145 correlated negatively in renal cancer tumor tissues and cell lines, suggesting
an important regulatory mechanism. Additionally, we showed that the regulation of ADAM17 is partly involved in the
effects of miR-145 on proliferation and migration, whereas no involvement in chemosensitivity was observed. Im-
portantly, in the healthy kidney, miR-145 was detected in different cell types including tubular cells, which are consid-
ered the origin of renal cancer. In renal cancer cell lines, miR-145 expression was strongly suppressed bymethylation.
In summary, miR-145 is downregulated in renal cancer patients, which leads to the up-regulation of ADAM17 in renal
cancer. Importantly, miR-145 and ADAM17 are regulated in a reciprocal negative feedback loop.
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Introduction
Renal cell carcinoma (RCC) originates from renal tubules and is the
most common cancer of the kidney, accounting for 90% to 95% of
all renal tumors in adults [1]. Importantly, 60% of all affected patients
develop metastases. Only 10% of RCC patients with metastases survive
longer than 5 years, whereas 80% of RCC patients with non-metastatic
disease survive 5 years or longer [2]. Given the scarce number of thera-
peutic regimens, alternative approaches are urgently needed to prolong
patient survival.
An interesting potential target molecule is the metalloprotease a dis-
integrin and metalloproteinase 17 (ADAM17), which is overexpressed
in several types of cancer, including renal cancer [3–11]. ADAM17
was originally identified as the protease of the tumor necrosis factor–α
(TNF-α), which is important during inflammation and for the cancer
microenvironment [12,13].
In RCC, ADAM17 expression increases with the degree of malig-
nancy and it is essential to form xenograft tumors [11,14]. Importantly,
more than 70 cellular substrates have been identified for ADAM17,
including TNF-α, transforming growth factor–α, and epidermal growth
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factor receptor (EGFR) ligands [15]. Interestingly, the expression levels
of members of the ADAM family can be regulated by small non-coding
microRNAs (miRNAs) [16–18]. Furthermore, miRNAs were shown to
have an important role in the regulation of gene networks, including
those that are essential for cancer development [19–21].
miRNA 145 (miR-145) plays a crucial role in the differentiation of
smooth muscle cells (SMCs) [22–24]. miR-145 is downregulated in
many tumors, including hematopoietic tumors and solid tumors of the
breast, ovary, head andneck, prostate, skin, lung, bladder, and cervix [25–
28]. Furthermore, the ectopic expression ofmiR-145 in cancer cells led to
a loss in cell viability and induced cell death [26,29,30]. It has been con-
sidered that the down-regulation of miR-145 is an early event in many
cancers, suggesting an important role in several cancer-related pathways
[31,32]. A number of genes that are important in different cancer path-
ways have been identified and validated as target genes of miR-145,
including plasminogen activator inhibitor-1 (PAI-1), octamer-binding
transcription factor 4 (Oct-4), sex determining region Y (SRY)-box 2
(Sox-2), c-Myc, and p70S6K1 [33–36]. miR-145 is downregulated by
promoter hypermethylation in many cancers [37–39]. Additionally, the
tumor suppressor gene p53, which is inactive in about 50% of all can-
cers, upregulates miR-145 expression, whereas, in contrast, the Ras
oncogene represses miR-145 expression [37,40]. It has been implicated
by Gregersen et al. that ADAM17 may be a target of miR-145 [41].
In this study, we identified miR-145 as an miRNA that is down-
regulated in the majority of renal cell cancers by methylation. Further-
more, we provide evidence that miR-145 decreases proliferation and
invasion by directly targeting the 3′ untranslated region (3′UTR) of
ADAM17 mRNA. Additionally, we show that ADAM17 negatively
regulates miR-145 expression through TNF-α, leading to a reciprocal
negative feedback loop. Importantly, we found a negative correlation
of miR-145 and ADAM17 expression in renal cancer samples, sug-
gesting that these molecules could be promising targets for further
treatment approaches.
Materials and Methods
Substances and Antibodies
To detect ADAM17 protein expression, we used the polyclonal
antibody from Santa Cruz Biotechnology (Heidelberg, Germany;
sc-13973). A β-actin antibody from Sigma-Aldrich (Taufkirchen,
Germany) was used as a loading control. The metalloprotease inhibitors
TAPI-0 and TAPI-2 were obtained from Calbiochem (Darmstadt,
Germany). Recombinant human TNF-α was purchased from Peprotech
(London, United Kingdom). Phorbol 12-myristate 13-acetate (PMA)
and 5-aza-2′-deoxycytidine (AZA) were obtained from Sigma (St Louis,
MO) and cisplatin from Teva (Radebeul, Germany).
Cell Culture
The renal carcinoma cell line A498 was obtained from Dr K.
Joehrer (Innsbruck Medical University, Innsbruck, Austria), whereas
the renal carcinoma cell line Foehn was a kind gift from Prof. Altevogt
(German Cancer Research Center, Heidelberg, Germany). The renal
carcinoma cell lines RCC4 and 786-0 were obtained from Prof. Krek
(ETH Zurich, Zürich, Switzerland). Protein isolation and Western
blot analyses were performed as previously described [42].
cDNA Synthesis and Polymerase Chain Reaction Analysis
RNA from cultured cells was isolated using the RNA Easy Kit accord-
ing to the manufacturer’s protocol (Qiagen, Hilden, Germany). Equal
amounts of total cellular RNA (1 μg) were reverse transcribed with ran-
dom primer by the use of M-MuLV Reverse Transcriptase (Fermentas,
St Leon-Rot, Germany). Transcribed cDNAs were used for polymerase
chain reaction (PCR) with specific primers for ADAM17 (435 bp,
5′-GCATTCTCAAGTCTCCACAAG-3′ and 5′-CCTCATTCGGG-
GCACATTCTG-3′), PAI-1 (183 bp, 5′-GAGGTGCCTCTCTCTG-
CCCTCACCAACATT-3′ and 5′-AGCCTGAAACTGTCTGAACAT-
GTCG-3′), c-Myc (478 bp, 5′-TACCCTCTCAACGACAGCAG-3′
and 5′-TCTTGACATTCTCCTCGGTG-3′), β-actin (234 bp, 5′-
GGACTTCGAGCAAGAGATGG-3′ and 5′-AGCACTGTGTTGG-
CGTACAG-3′), and pri-miR-145 (73 bp, 5′-TGGATTTGCCTCCT-
TCCCA-3′ and 5′-TTGAACCCTCATCCT GTGAGCC-3′). The
method described by Chen et al. was followed for stem-loop reverse tran-
scription of mature miRNAs [43]. For miR-145, the stem-loop primer
5′-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTG-
GATACGACAGGGAT-3′ was used, and for U48, the stem-loop
primer 5′-GTTGGCTCTGGTGCAGGGTCCGAGGT-ATTCGC-
ACCAGAGCCAACGGTCAG-3′ was used. For miR-143, the com-
mercially available primers from Exiqon (Vedbaek, Denmark) were
used (#204190). The reverse transcribed product of miR-145 was then
amplified by PCR with specific primers (5′-CGGCGTCCAGTTTT-
CCCAGG-3′ and 5′-GTGCAGGGTCCGAGGT-3′, and for U48,
5′-CGACGAGTGATGATGAC-3′ and 5′-GTGCAGGGTCCG-
AGGT-3′).
Real-time PCR
Real-time PCR was performed as described in the protocol from
the Absolute Blue QPCR SYBR Green Low ROX Kit (Thermo
Scientific, Hilden, Germany). The same primers as for the conven-
tional PCR were also used for the real-time PCR. The CT values of
analyzed RNA levels were normalized to the CT values of β-actin for
mRNA and for miR-145 to U48 (housekeeping miRNA) within the
same sample.
Luciferase Constructs
To construct luciferase reporter plasmids, we inserted various target
fragments into multiple cloning site (MCS; XhoI and NotI) down-
stream of the Renilla luciferase reporter gene in the psiCHECK-2
promoter vector (Promega, Madison, WI). 5′ Modified primers carry-
ing restriction sites for either XhoI or NotI were used (sequence printed
in bold). The sequence from 3075 to 3082 (5′-AACTGGAA-3′) in
the human ADAM17 mRNA (NM_003183.4) was termed miR-145
binding site.
The 761-nt fragment of the ADAM17 3′UTR (2613-3373, NM_
003183.4) was generated using the following primer set: forward,
5′-atactcgagACTGCAGCGTCAGAATCGTGTTGA-3′ and reverse,
5′-atagcggccgcCCCAGCAAATCAGGGCCCTAAACA-3′.
Site-directed mutagenesis of the miR-145 binding site in the
ADAM17 3′UTRwas carried out with the QuickChange Site-Directed
Mutagenesis Kit (Stratagene, La Jolla, CA), using the following
primers: 5′-GAGGCATTTGGCATTTATTTGTGATGACAgcaga-
aATAGTTTTTTT-3′ and 5′-AAAAAAACTATttctgcTGTCATCAC-
AAATAAATGCCAAATGCCTC-3′.
A fragment containing the perfect matching sequence with the ma-
ture miR-145, 5′-atactcgagAGGGATTCCTGGGAAAACTGGAC-
gcggccgcata-3′ (the matching sequence is underlined), was cloned
(psiCHECK-2-p145). All constructs were sequenced.
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Luciferase Assay
Human embryonic kidney 293 (HEK293) cells (3 × 105 per six-well
plate) were transfected using the Lipofectamine 2000 transfection
reagent (Invitrogen, Carlsbad, CA). Control RNA (20 nM) or miR-
145 was co-transfected with 400 ng of appropriate plasmids and lysed
for luciferase assay 24 hours after transfection. Luciferase assays were per-
formed using a Dual-Luciferase Reporter Assay System (Promega)
according to the manufacturer’s protocol. Firefly luciferase was used
for normalization.
Oligonucleotide Transfection
The following siRNA duplexes (MWG Biotech AG, Ebersberg,
Germany) were used for down-regulation of the corresponding protein
expression: ADAM17-siRNA, 5′-GAGAAGCUUGAUUCUUUG-
CTT-3′. The transfection of miR-145 mimic (10 nM), miR-145 inhib-
itor (10 nM; both Qiagen), and miR-143 locked nucleic acid (LNA;
Exiqon) inhibitors was performed in the same manner. As negative
controls, unspecific AllStars negative control RNA from Qiagen or
LNA control from Exiqon was used. Twenty-four hours before transfec-
tion, 0.4 × 105 cells were seeded in six-well plates. Transfection of siRNA
was carried out using Oligofectamine (Invitrogen, Karlsruhe, Germany)
together with 10 nM siRNA duplex per well as previously described [44].
Immunohistochemistry and In Situ Hybridization
The in situ hybridization was performed with a 3′ and 5′ double DIG-
labeled LNA miR-145 probe (Exiqon). The hybridization protocol has
been described in detail by Jorgensen et al. [45]. After miR-145 staining,
development and immunohistochemistry staining, starting with the first
antibody, was continued with the same slide. Immunohistochemistry
has been previously described [46].
Cell Cycle Analysis
Seventy-two hours after transfection, cells were trypsinized, washed
in phosphate-buffered saline, and fixed with 70% ethanol at −20°C.
After centrifugation, cells were incubated in hypotonic solution con-
taining 50 μg/ml propidium iodide, 0.1% sodium citrate, 0.1% Triton
X-100, and 20 μg/ml DNase-free RNaseA for 30 minutes at 37°C.
Finally, cells were analyzed using flow cytometry in a linear mode. Each
assay was performed in triplicates and repeated at least three times.
Patient Material
Tumor specimens and adjacent normal kidney tissues were col-
lected from a total of 15 patients undergoing nephrectomy for RCC.
All specimens were obtained on the basis of their availability for
research purpose and under a protocol approved by the local medical
ethics committee of Goethe University Frankfurt. Written consent was
obtained from the patients in the study.
Cell Invasion Assay
The cell migration assay has been described earlier [47].
Proliferation Assay
The proliferation assay has been previously described [48].
Statistical Analysis
If not otherwise indicated in the figure legends, Student’s t test was
used for statistical analyses.
Results
miR-145 Downregulates ADAM17 Protein Expression in
Renal Cancer Cell Lines
The computational algorithms TargetScan, PicTar, and miRANDA
were used to identify miRNAs that could potentially regulate ADAM17
expression [49–51]. These programs search for miRNAs that target
evolutionary conserved sequences in the 3′UTR of the mRNA of the
molecule of interest. miR-145 was one of two miRNAs predicted by
all three programs to bind to the ADAM17 3′UTR (Figure 1, A and
B). Importantly, it was shown in three microarray studies by miRNA
profiling of renal cancer patients that miR-145 is regulated in cancer
tissue [52–54].
Next, we investigated the miR-145 levels in a primary renal tubular
cell line and in four renal cancer cell lines. The primary renal tubular
cell line HRCepiC expressed higher levels of miR-145 than the renal
cancer cell lines RCC4, 786-0, A498, and Foehn (Figure 1C ). In
contrast, the tubular cell line HRCepiC expressed the lowest amounts
of ADAM17 protein and mRNA when compared to renal cancer cell
lines (Figure 1, D and E).
To analyze the miR-145 and ADAM17 expression in renal cancer
patients, we isolated renal cell cancer and corresponding normal kidney
RNA from 15 patients and analyzed the expression levels by real-time
PCR (Figure 1F). Interestingly, in only one tumor specimen, miR-145
was moderately upregulated (+3.8); in four renal cancer tissues, it was
virtually unchanged (+1.4 to −1.1), while in 10 renal cancer tissues,
it was downregulated, ranging from 1.7-fold to more than 65-fold
down-regulation, with an overall average of 8.9-fold down-regulation
(P < 10−4). In contrast, only one patient displayed a decrease in
ADAM17 expression (1.9), whereas six displayed almost no change
(+1.2 to −1.4) and eight showed an up-regulation (+1.6 to +5.8) in
tumor tissue compared to normal tissue with an overall average of
1.2-fold increase (P < .05).
The expression of miR-145 was further plotted versus the mRNA
expression of ADAM17 for every individual patient (Figure 1G). Inter-
estingly, all patient values were plotted in a small corridor, with the ex-
ception of patient number 218 that displayed the strongest decrease
in miR-145 (−65.2) and ADAM17 (−1.9) expression. When analyzing
the values in the marked corridor (14 of 15 patients), miR-145 and
ADAM17 showed a significant negative correlation (K = −0.67), pro-
viding evidence for the regulation of ADAM17 by miR-145 in vivo.
In contrast, when analyzing the known genes c-Myc and PAI-1, which
have been described as miR-145 target genes, we could not find a
correlation (Figure 1, H and I).
To determine the localization of miR-145 in normal human renal
tissue, we performed in situ hybridization with miR-145–specific
probes, followed by immunohistochemical staining with an antibody
against aquaporin-1, which is known as a marker of proximal tubules
[55]. miR-145 was strongly expressed in SMCs of blood vessels and
inside the glomerulus (Figure 1, I , K , and N ). Additionally, tubules
adjacent to glomeruli and small tubules displayed distinct miR-145
expression (Figure 1, M and N ).
miR-145 Regulates ADAM17 Expression through Direct
Binding to the 3′UTR
Next, we evaluated the ability to inhibit or overexpress miR-145 using
a commercial miR-145 inhibitor or mimic in the renal cancer cell lines
A498 and Foehn. The cells were transfected with miR-145 inhibitor,
the miR-145 mimic, or a control RNA. Transfection efficiency was
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measured by reverse transcription–PCR, which demonstrated that
the miR-145 levels were efficiently changed (Figure W1, A and B).
The reduction of miR-145 after inhibitor transfection indicates a deg-
radation of mature miR-145 [56]. Importantly, in A498 and Foehn
cells, the transfection of miR-145 mimic led to a strong reduction
in ADAM17 protein expression, whereas the transfection with the
miR-145 inhibitor increased ADAM17 protein expression in both cell
lines (Figure 2, A and B).
To investigate whether miR-145 represses ADAM17 expression
through direct binding on the ADAM17 3′UTR, we introduced
the predicted miR-145 binding site into the 3′UTR of a luciferase
reporter gene. We found that the transfection of HEK293 cells with
miR-145 mimics reduced the luciferase activity significantly, whereas
it had no effects on the mutated binding site (Figure 2C ).
Taken together, we observed that miR-145 regulates the protein
expression of ADAM17, which might be due to the direct interaction
of miR-145 with the 3′UTR of ADAM17 mRNA.
Inhibition of miR-143 Reduces ADAM17 Expression in
Renal Cancer Cells
Because miR-145 is transcribed in a cluster with miR-143, and
both have been shown to work synergistically in several cell models,
we analyzed the expression of miR-143 in our renal cancer cell model.
When comparing different renal cancer cell lines, the A498 cell
line had the highest, whereas Foehn cells had the lowest expression
of miR-143 (Figure 3A). The transfection of the Foehn cells with
miR-145 mimic leads to an increase in miR-143 levels, whereas in the
Figure 1. miR-145 regulates ADAM17 expression in renal cancer cell line. (A) Predicted duplex formation between human miR-145 (hsa-
miR-145; top) and human ADAM17 3′UTR (bottom). (B) Sequence of the miR-145 binding site within the ADAM17 3′UTR of human (Hsa),
chimpanzee (Ptr), Rhesus macaque (Mml), mouse (Mmu), and rat (Rno). (C) Relative real-time PCR of miR-145 expression in relation to U48
expression in HRCepiC, RCC4, 786-0, A498, and Foehn cells. (D) Western blot analysis for ADAM17 (A17) of total lysates of HRCepiC, RCC4,
786-0, A498, and Foehn cells. β-Actin antibody was used as a loading control. The densitometrical analysis of the ADAM17 expression to
β-actin is additionally depicted. (E) Relative real-time PCR of ADAM17 mRNA expression in relation to β-actin expression in HRCepiC, RCC4,
786-0, A498, and Foehn cells. (F) Real-time PCR of miR-145 expression relative to U48 expression in RCC tissue compared to normal renal
tissue of 15 renal cancer patients (bright gray bars) and real-time PCR of ADAM17 expression in RCC tumor samples compared to normal
renal tissue of the same patients (dark gray bars). The values were evaluated with the Δ-Δ CT method. Correlations were calculated with
Student’s t test, normal tissue against tumor tissue for miR-145 and ADAM17. (G) Plot of fold change of miR-145 related to fold change of
ADAM17 for each patient; r, Pearson correlation coefficient; a, regression line. (H) Plot of fold change of miR-145 related to fold change of
c-Myc for each patient. (I) Plot of fold change of miR-145 related to fold change of PAI-1 for each patient. (J) Overview of a tissue section of a
normal kidney stained by in situ hybridization for miR-145 (blue) and by immunohistochemistry with an aquaporin-1 (red)–specific antibody.
Scale bar represents 300 μm. (K) Enlarged picture of J showing the miR-145–expressing blood vessel. Scale bar represents 300 μm.
(L) Enlarged picture of J. Scale bar represents 300 μm. (M) Enlarged picture of I showing miR-145–expressing (blue) and aquaporin-1
(red)–expressing tubular cells. Scale bar represents 50 μm. (N) Section of a glomerulus of a normal kidney stained by in situ hybridization
for miR-145 (blue) and by immunohistochemical analysis for aquaporin-1 (red). Scale bar represents 50 μm.
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A498 cells this leads to a decrease of miR-143 expression (Figure 3, B and
C). Interestingly, when we transfected the A498 cells with an miR-143
inhibitor, it led to a decrease in miR-145 expression (Figure 3D). Surpris-
ingly, the inhibition of miR-143 led to a reduction of ADAM17 protein
expression but showed that miR-143 and miR-145 do not regulate
ADAM17 synergistically (Figure 3E).
ADAM17 Is Involved in the Effects of miR-145 on
Proliferation and Invasion
To assess the functional role of miR-145 in renal cancer cells, we
transfected Foehn cells with the miR-145 inhibitor and proliferation
was measured (Figure 4A). Interestingly, miR-145 inhibitor–treated
cells proliferated faster than control cells, whereas transfection with
Figure 1. (continued).
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the miR-145 mimic led to a significant reduction in cell prolifera-
tion (Figure 4B). A cell cycle analysis was performed to determine
the role of miR-145 in the regulation of the cell cycle. Importantly,
the miR-145 mimic led to a 65% increase in cells in sub-G1/G0,
whereas the miR-145 inhibitor led to a significant reduction of
cells in sub-G1/G0 (Figure 4C ). The sub-G1/G0 phase represents
cells that harbor a fragmented nucleus, which is an early event dur-
ing apoptosis in which endonucleases start to cleave the genomic
DNA [57].
We further observed that the amount of S-phase cells decreased after
miR-145 transfection and increased significantly after transfection
with miR-145 inhibitor. Because the S-phase represents cells during
genome duplication, it can be used as an indirect measurement of cell
proliferation (Figure 4C ). Similar effects on cell cycle and proliferation
were observed in A498 cells (Figure W2, A and B).
The role of miR-145 was further analyzed in RCC4 cells, which
expressed the highest miR-145 levels. The transfection of RCC4 cells
with miR-145 mimic and inhibitor was assessed by real-time PCR
(Figure W1C ). Interestingly, in contrast to Foehn and A498 cells,
the transfection of miR-145 did not induce apoptosis in RCC4
cells (Figure 4D). Although no direct influence on cell death was
observed, the role of miR-145 in the resistance of renal cancer cells
against the chemotherapeutic reagent cisplatin (CDDP) was further
investigated. Transfection of miR-145 mimic significantly increased
the amount of apoptotic cells after the treatment with CDDP (Fig-
ure 4D). In contrast, the transfection with miR-145 inhibitor signifi-
cantly reduced the number of cells in sub-G1/G0 CDDP treated and
untreated (Figure 4E).
To investigate whether ADAM17 is involved in miR-145–regulated
proliferation, RCC4 cells were transfected with miR-145 inhibitor
and additionally with ADAM17 siRNA. The induced proliferation rate
after transfection with miR-145 inhibitor was partially inhibited when
ADAM17 was also silenced (Figure 4F). Similarly, increased invasion
after miR-145 inhibition was partly abrogated by the down-regulation
of ADAM17 (Figure 4G ). In contrast, miR-145 inhibitor together
with ADAM17 siRNA did not change the chemoresistance of RCC4
cells against CDDP when compared to the transfection of miR-145
inhibitor alone (Figure 4H ). The down-regulation of ADAM17 by
Figure 2. miR-145 binds directly to the 3′UTR of ADAM17 mRNA. (A) Western blot analysis for ADAM17 of total lysates of Foehn cells
transfected with control RNA (ctrl RNA), miR-145 mimic (miR-145), miR-145 inhibitor (miR-145 inh), or specific siRNA against ADAM17
(A17-siRNA). β-Actin was used to determine equal loading. The densitometrical analysis of the ADAM17 expression to β-actin is additionally
depicted (n= 4). (B) Western blot analysis for ADAM17 of total lysates of A498 cells transfected with control RNA (ctrl RNA), miR-145mimic
(miR-145), miR-145 inhibitor (miR-145 inh), or specific siRNA against ADAM17 (A17-siRNA). β-Actin was used to determine equal loading.
The densitometrical analysis of the ADAM17 expression to β-actin is additionally depicted (n = 3). (C) Luciferase assays with reporter
constructs containing either ADAM17 3′UTR with the predicted miR-145 binding site or the mutated binding site. Furthermore, a reporter
construct carrying the complement sequence of the mature form of miR-145 was transfected as positive control. The Renilla luciferase
activity for each construct was normalized with firefly luciferase activities. Fold change = (S renilla/S firefly)/(C renilla/C firefly).
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miR-145 in RCC4 cells was confirmed by Western blot analysis
(Figure 3I). ADAM17 siRNA alone had no effect on proliferation or
invasion in RCC4 cells (Figure W3, A and B).
ADAM17 Regulates miR-145 in a Reciprocal Negative
Feedback Loop
Because it has been demonstrated that various miRNAs, including
miR-145, can be regulated by positive or negative feedback loops,
we analyzed whether also ADAM17 is able to regulate miR-145
expression [30,58,59].
Importantly, the down-regulation of ADAM17 led to a seven-fold in-
duction of miR-145 expression (Figure 5A). One of the most prominent
substrates of ADAM17 is TNF-α. To analyze whether the increase of
miR-145 expression was mediated through the reduced cleavage of
TNF-α, we treated the cells with recombinant TNF-α for 1 day, 48 hours
after siRNA transfection. Importantly, TNF-α reduced the expression of
miR-145 in the control transfected cells to about 40% (Figure 5A). In
contrast, the seven-fold induction of miR-145 expression after ADAM17
down-regulation was abrogated by the addition of recombinant TNF-α
(Figure 5A). These results suggest that the reduced cleavage of TNF-α
after ADAM17 down-regulation leads subsequently to the up-regulation
of miR-145.
To substantiate this hypothesis, we treated the cells with the
metalloprotease inhibitor TAPI-2 or the ADAM17-specific inhibitor
TAPI-0, and miR-145 expression was assessed. Importantly, TAPI-0
and TAPI-2 increased the miR-145 expression about two-fold
(Figure 5B). In contrast, TNF-α and PMA stimulation, which activates
the shedding of ADAM17 substrates, lead to the reduction of miR-145
expression. Interestingly, when analyzing both the miR-145 and
ADAM17 expression after the treatment with TNF-α, the ADAM17
expression increases five-fold in contrast to miR-145 expression
(Figure 5C). Therefore, our data suggest that the soluble factors cleaved
by ADAM17 could be major regulators of miR-145 expression. The
regulation of miR-145 by ADAM17 was further validated in Foehn
cells (Figure 5D).
miR-145 Is Downregulated by Promoter Methylation
Because it is known from prostate cancer that miR-145 is down-
regulated by methylation, we examined whether methylation could
also regulate miR-145 expression in renal cancer cells [37]. To test this
hypothesis, we treated the cell lines A498, RCC4, and Foehn with
AZA for 4 days. AZA leads to the demethylation of the DNA by
inhibiting the DNA methyltransferase. AZA treatment resulted in an
approximately 10-fold increase of mature miR-145 in A498 cells and
a more than 40-fold increase in RCC4 and Foehn cells (Figure 6A).
Because the increase should be reflected by an increase of the primary
transcript, we measured the pri-miR-145, which shows no difference
in A498 cells but a three-fold up-regulation in RCC4 and a six-fold
up-regulation in Foehn cells (Figure 6B). In contrast, mature miR-143
expression, which is transcribed in a cluster with miR-145, showed no
change in these cell lines (Figure 6C).
To determine whether the increase of miR-145 after demethylation
regulates also ADAM17 expression, we measured ADAM17 protein
expression after AZA treatment. In line with the previous results, all
Figure 3. Inhibition of miR-143 reduces ADAM17 expression. (A) Relative real-time PCR of miR-143 expression in relation to U48 expression
in RCC4, Foehn, and A498 cells. (B) Relative real-time PCR of miR-143 expression in relation to U48 expression in Foehn cells that were
transfected with control RNA (ctrl RNA) or miR-145 mimic (miR-145). (C) Relative real-time PCR of miR-143 expression in relation to U48
expression in A498 cells that were transfected with control RNA (ctrl RNA) or miR-145 mimic (miR-145). (D) Relative real-time PCR of
miR-143 and miR-145 expression in relation to U48 expression in A498 cells that were transfected with control LNA (ctrl LNA) or
miR-143 LNA. (E) Western blot analysis for ADAM17 (A17) of total lysates of D. β-Actin antibody was used as a loading control.
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tested renal cancer cell lines displayed a reduced ADAM17 expression
after AZA treatment (Figures 6D and 7).
Discussion
RCC is characterized by its resistance to current standard ther-
apies [60]. Despite the rapid progress in the understanding of
the molecular mechanisms of RCC, new treatment strategies are
urgently needed.
In this context, ADAM metalloproteases are a promising family of
proteins that are upregulated in several cancers [61]. miRNAs have
been shown to be involved in the regulation of members of the ADAM
family [16–18]. Furthermore, it has been demonstrated that the
non-coding miRNAs have a versatile role for the regulation of genes
during cancer development [62]. In the present study, miR-145 was
identified as an miRNA that negatively regulates ADAM17. The
binding was predicted by three different computational algorithms,
providing a high probability that miR-145 would also regulate
Figure 4. miR-145 reduces proliferation by induction of apoptosis. (A) Foehn cells were transfected with control RNA (ctrl RNA) or miR-145
inhibitor (miR-145 inh). Twenty-four hours after RNA transfection, anchorage-dependent cell growth was measured at the time points 24,
48, and 72 hours after RNA transfection using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (n = 3). (B) Foehn
cells were transfected with control RNA (ctrl RNA) or miR-145 mimic (miR-145). Twenty-four hours after RNA transfection, anchorage-
dependent cell growth was measured at the time points 24, 48, and 72 hours after siRNA transfection using an MTT assay (n = 3).
(C) Foehn cells were transfected with control RNA (ctrl RNA), miR-145 mimic (miR-145), or miR-145 inhibitor (miR-145 inh). Cell cycle analy-
sis was performed as described in Materials and Methods section. The percentages of Foehn cells in the sub-G1/G0 (apoptosis), G1 (haploid
genome), S (DNA synthesis), or G2 (diploid genome) phase are depicted (n = 3). (D) RCC4 cells were transfected with control RNA (ctrl
RNA) or miR-145 mimic (miR-145). Forty-eight hours after transfection, 10 μg/ml cisplatin (CDDP) was added to the cells for 24 hours. Cells
were harvested andmeasured by cell cycle analysis as described inMaterials andMethods section. The percentage of cells in the sub-G1/G0
(apoptosis), G1 (haploid genome), S (DNA synthesis), or G2 (diploid genome) phase is displayed in a graph (n = 3). (E) RCC4 cells were
transfected with control RNA (ctrl RNA) or miR-145 inhibitor (miR-145 inh). Forty-eight hours after transfection, 10 μg/ml CDDP was added
to the cells for 24 hours. Cells were harvested and measured by cell cycle analysis as described in Materials and Methods section. The
percentage of cells in the sub-G1/G0 (apoptosis), G1 (haploid genome), S (DNA synthesis), or G2 (diploid genome) phase is displayed (n =
3). (F) RCC4 cells were transfected with control RNA (ctrl RNA), miR-145 inhibitor (miR-145 inh), or miR-145 inhibitor with ADAM17 siRNA
(miR-145 inh + A17si). Twenty-four hours after RNA transfection, anchorage-dependent cell growth was measured at the time points 24,
48, and 72 hours after RNA transfection using anMTT assay. (G) RCC4 cells were transfected with control RNA (ctrl RNA), miR-145 inhibitor
(miR-145 inh), or ADAM17 siRNA together with miR-145 inhibitor (miR-145 inh + A17si). Invasion assay was performed using matrigel-
coated transwell chambers. (H) RCC4 cells were transfected with control RNA (ctrl RNA), miR-145 inhibitor (miR-145 inh), or ADAM17 siRNA
together with miR-145 inhibitor (miR-145 inh + A17si). The percentage of cells in the sub-G1/G0 (apoptosis) phase is displayed in a graph.
(I) RCC4 cells were transfected with control RNA (ctrl RNA), miR-145 inhibitor (miR-145 inh), or ADAM17 siRNA together with miR-145
inhibitor (miR-145 inh + A17si). Cell lysates were investigated by Western blot using antibodies against ADAM17 (A17) and β-actin as a
loading control. The densitometrical analysis of the ADAM17 expression to β-actin is additionally depicted. *P < .05, **P < .01, and
P < .001 are considered statistically significant. ns, not significant.
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ADAM17 directly under physiological conditions. The binding has
been additionally suggested by Gregersen et al. [41]. The regulation
of ADAM17 by miR-145 was shown in different renal cancer cell
lines by the transfection of miR-145 mimic as well as by inhibiting
miR-145 expression. The overexpression of miR-145 led to massive
reduction in ADAM17 protein expression, whereas the inhibition of
miR-145 increased the amount of ADAM17, demonstrating the im-
portance of miR-145 in the regulation of ADAM17. By performing
mRNA reporter assay, we could show that miR-145 can directly bind
to the predicted 3′UTR of ADAM17 mRNA.
The idea that miR-145 has also a role in the regulation of ADAM17
was supported by the finding that cancer cell lines have reducedmiR-145
expression and increased ADAM17 expression when compared to renal
tubular control cell line. Importantly, miR-145 is downregulated in
many cancers, whereas different studies demonstrated that ADAM17
was upregulated in the same cancer types [3–11,25–28]. In this study,
we could show that, in most renal cancer patients, miR-145 is down-
regulated, whereas ADAM17 is upregulated. Moreover, the analysis of
RCC patients revealed a significantly negative correlation of ADAM17
and miR-145, indicating that both genes are tightly regulated. Interest-
ingly, the patient that was not included in the correlation had the worst
clinical outcome with the highest number of metastases. This patient
expressed the lowest relative amount of ADAM17 and miR-145, which
could indicate that at this late stage ADAM17 might be downregulated
by factors independent of miR-145. In agreement with our results,
the down-regulation of miR-145 has been considered as an early event
in other cancers, which has an influence on several tumor-promoting
pathways [31,32].
miR-145 has been shown to be expressed in vascular SMCs, playing
an essential role for smooth muscle development [22–24]. Similarly,
Figure 4. (continued).
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we could detect strong miR-145 expression in vascular SMCs of the
kidney. Additionally, we observed miR-145 expression in glomeruli
and renal tubules, where the predominantly smaller tubules were posi-
tive for miR-145. In addition to the glomeruli, the Bowman’s capsule
and adjacent tubules expressed miR-145. These data suggest a role for
miR-145 in normal adult glomeruli and renal tubules.
Our findings that miR-145 reduces proliferation and induces
apoptotic cell death in renal cancer cells are in agreement with the
results in other cancer types [36,58,63]. It was further demonstrated
that ADAM17 is partially involved in the effects of miR-145 on
proliferation and invasion, suggesting a role of additional target genes.
Particularly, the regulation of the p53 repressor MDM2 by miR-145
could play a major role for the changes in cell cycle, chemoresistance,
and proliferation [58]. Additionally, it was shown that miR-145 targets
P70S6K1, which is important for the activation of the phosphatidyl-
inositide 3-kinases (PI3K)/Akt pathway, resulting in reduced tumor
growth [36].
We also demonstrated that not only miR-145 negatively regulates
ADAM17 but ADAM17 also downregulates the miR-145 reciprocal
negative feedback loop. Positive and negative feedback loops have been
described for many miRNAs, including miR-145 [30,58,59]. Similarly
to our work, Xu and colleagues observed a reciprocal negative feed-
back loop of miR-145 and Oct4, resulting either in pluripotent cells
with low miR-145 expression or differentiated cells with high levels
of miR-145 [35].
Reciprocal negative and positive feedback loops are often asso-
ciated with a cell type switch that leads to a long-lasting cellular
response [64,65].
Importantly, we showed that this regulation is transmitted by cleaved
substrates of ADAM17, like TNF-α. TNF-α levels are often increased
in the tumor microenvironment by tumor cells and by stroma cells,
leading to a more tumorigenic tumor and increased metastasis. It
would be interesting to investigate whether inhibition of the ADAM17
cleavage by specific inhibitors could reduce the cleaved substrates in
the microenvironment and increase the miR-145 expression in tumor
cells in vivo, thus resulting in better treatment options. Similar to
our results, up-regulation of miR-145 in many cancer types induces
antitumor properties like sensitivity toward chemotherapeutic treat-
ment [26,29,30]. Moreover, we demonstrated that miR-145 is down-
regulated by methylation, which is in agreement with studies in other
Figure 5. ADAM17 regulates miR-145 expression by cleavage of TNF-α. (A) Real-time PCR of miR-145 relative to U48 expression in RCC4
cells after transfection with either control RNA (ctrl RNA) or specific ADAM17 siRNA (A17-siRNA). Forty-eight hours after transfection, the
cells were treated with control vehicle (bright bars) or with 10 nM TNF-α (dark bars). The Western blot analysis for ADAM17 (A17) of total
lysates to control the efficient down-regulation is additionally depicted. β-Actin antibody was used as a loading control. (B) Real-time PCR of
miR-145 expression relative to U48 expression in RCC4 cells after treatment for 24 hours with either control vehicle (ctrl), PMA (100 ng/ml),
TNF-α (10 nM), or the metalloprotease inhibitors TAPI-0 and TAPI-2 (both 10 μM). *P < .05, **P < .01, and ***P < .001 are considered
statistically significant. (C) Real-time PCR of miR-145 expression relative to U48 expression (gray bars) and ADAM17 expression to β-actin
expression (black bars) in RCC4 cells after treatment for 24 hours with either control vehicle (ctrl) or TNF-α (10 nM). (D) Real-time PCR of
miR-145 expression relative to U48 expression in Foehn cells after transfection with either control RNA (ctrl RNA, bright bars) or specific
ADAM17 siRNA (A17-siRNA, dark bars). TheWestern blot analysis for ADAM17 (A17) of total lysates to control the efficient down-regulation
is additionally depicted. β-Actin antibody was used as a loading control.
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cancer types [37–39]. The strong induction of miR-145 after the
addition of the demethylation agent in three cell lines indicates a direct
methylation of miR-145 and not a secondary effect through a sec-
ondary regulator. Interestingly, we observed an increase of mature
miR-145 that was about 10 times higher than the amount of the
primary transcript. It could be that the treatment with AZA also
increases the processing of primary miR-145 to the mature form. In
contrast, no strong differences in mature miR-143, which is transcribed
as a cluster together with miR-145, were observed, and this might be
due to differences in processing.
Figure 6. miR-145 is downregulated by methylation in renal cancer cells. (A) Real-time PCR of miR-145 expression relative to U48 ex-
pression in A498, RCC4, and Foehn cells after treatment with either control vehicle (ctrl, bright bars) or AZA (10 μM, dark bars) for
72 hours. (B) Real-time PCR of pri-miR-145 expression relative to β-actin expression in A498, RCC4, and Foehn cells after treatment
with either control vehicle (ctrl, bright bars) or AZA (10 μM, dark bars) for 72 hours. (C) Real-time PCR of miR-143 expression relative
to U48 expression in A498, RCC4, and Foehn cells after treatment with either control vehicle (ctrl, bright bars) or AZA (10 μM, dark bars)
for 72 hours. (D) A498, RCC4, and Foehn cells after treatment with either control vehicle (−) or AZA (10 μM, +) for 72 hours. Cell lysates
were investigated by Western blot analysis with antibodies against ADAM17 and β-actin as a loading control.
Figure 7. Reciprocal negative feedback loop of miR-145 and ADAM17 is transmitted through TNF-α. (A) Endogenous expression of
miR-145 in normal kidney cells leads to the down-regulation of ADAM17 expression. As a consequence, less substrates are released
by ADAM17, leading to an even higher expression of miR-145. As a result, ADAM17 is weakly expressed, whereas the miR-145 expres-
sion is high. (B) miR-145 expression is suppressed in renal cancer cells by an initial event, like promoter methylation. This leads to an
up-regulation of ADAM17 expression, resulting in an increase of ADAM17-mediated cleavage of substrates like TNF-α. The released
substrates then further suppress the expression of miR-145, leading to a reciprocal negative feedback loop. As a result, ADAM17
expression is elevated in renal cancer patients, whereas miR-145 is downregulated.
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In the future, it would be important to analyze the methyla status
of renal cancer patients. Given that, demethylation agents could be
an important treatment option to increase miR-145 expression in
renal cancer cells and thus sensitize renal cancer cells for therapy.
In summary, the data of the present work demonstrated that
miR-145 is a tumor-suppressive miRNA in RCC that regulates the
metalloprotease ADAM17. It could be a novel treatment strategy to
increase the miR-145 expression by demethylation or by inhibiting
the ADAM17 cleavage in renal cancer patients.
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Figure W1. (A) Real-time PCR of miR-145 relative to U48 expression in Foehn cells after the transfection with control RNA (ctrl RNA),
miR-145 mimic (miR-145), or miR-145 inhibitor (miR-145 inh). (B) Real-time PCR of miR-145 relative to U48 expression in A498 cells after
the transfection with control RNA (ctrl RNA), miR-145 mimic (miR-145), or miR-145 inhibitor (miR-145 inh). (C) Real-time PCR of miR-145
expression relative to U48 expression in RCC4 cells after transfection with either control RNA (ctrl RNA), miR-145 mimic (miR-145), or
miR-145 inhibitor (miR-145 inh).
Figure W2. (A) A498 cells were transfected with control RNA (ctrl RNA) or miR-145 mimic (miR-145). Twenty-four hours after RNA trans-
fection, anchorage-dependent cell growth was measured at the time points 24, 48, and 72 hours after siRNA transfection using an MTT
assay (n = 3). (B) A498 cells were transfected with control RNA (ctrl RNA) or miR-145 mimic (miR-145). Cell cycle analysis was performed
as described in Materials and Methods section. The percentages of Foehn cells in the sub-G1/G0 (apoptosis), G1 (haploid genome),
S (DNA synthesis), or G2 (diploid genome) phase are depicted (n = 3). **P < .01 and ***P < .001 are considered statistically significant.
ns, not significant.
Figure W3. (A) RCC4 cells were transfected with control RNA (ctrl RNA) or ADAM17 siRNA (A17-siRNA). Twenty-four hours after RNA
transfection, anchorage-dependent cell growth was measured at the time points 24, 48, and 72 hours after RNA transfection using an
MTT assay. (B) RCC4 cells were transfected with control RNA (ctrl RNA) or ADAM17 siRNA (A17-siRNA). Invasion assay was performed
using matrigel-coated transwell chambers.
